|
Volumn 8, Issue 25, 2002, Pages 2249-2253
|
BAY 43-9006: Early clinical data in patients with advanced solid malignancies
a a |
Author keywords
BAY 43 9006; Efficacy; Pharmacokinetics; Phase I study; Raf kinase; Review; Solid tumours; Toxicity
|
Indexed keywords
MITOGEN ACTIVATED PROTEIN KINASE;
PROTEIN KINASE;
PROTEIN KINASE INHIBITOR;
RAF PROTEIN;
RAS PROTEIN;
SORAFENIB;
UNCLASSIFIED DRUG;
ABDOMINAL CRAMP;
AREA UNDER THE CURVE;
ARTICLE;
CELL GROWTH;
CHEILITIS;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIARRHEA;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG TOLERABILITY;
FOOD DRUG INTERACTION;
GASTROINTESTINAL TOXICITY;
HUMAN;
MAJOR CLINICAL STUDY;
NAUSEA;
PHASE 1 CLINICAL TRIAL;
PHENOTYPE;
PRIORITY JOURNAL;
PROTEIN FUNCTION;
PRURITUS;
RASH;
SIGNAL TRANSDUCTION;
SKIN TOXICITY;
SOLID TUMOR;
ANIMALS;
ANTINEOPLASTIC AGENTS;
BENZENESULFONATES;
CLINICAL TRIALS, PHASE I;
HUMANS;
NEOPLASMS;
PYRIDINES;
|
EID: 0036402628
PISSN: 13816128
EISSN: None
Source Type: Journal
DOI: 10.2174/1381612023393053 Document Type: Article |
Times cited : (98)
|
References (16)
|